Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:54AM ET
2.07
Dollar change
+0.01
Percentage change
0.24
%
IndexRUT P/E- EPS (ttm)-0.83 Insider Own40.74% Shs Outstand151.09M Perf Week-3.95%
Market Cap312.00M Forward P/E- EPS next Y-0.97 Insider Trans3.43% Shs Float89.54M Perf Month-12.13%
Income-125.04M PEG- EPS next Q-0.22 Inst Own37.35% Short Float10.08% Perf Quarter-3.95%
Sales0.00M P/S- EPS this Y-31.93% Inst Trans3.21% Short Ratio11.55 Perf Half Y-4.84%
Book/sh2.10 P/B0.99 EPS next Y11.67% ROA-27.48% Short Interest9.02M Perf Year-24.64%
Cash/sh2.07 P/C1.00 EPS next 5Y- ROE-34.33% 52W Range1.51 - 3.38 Perf YTD-3.05%
Dividend Est.- P/FCF- EPS past 5Y-69.36% ROI-33.93% 52W High-38.81% Beta1.11
Dividend TTM- Quick Ratio12.26 Sales past 5Y0.00% Gross Margin- 52W Low36.75% ATR (14)0.18
Dividend Ex-Date- Current Ratio12.26 EPS Y/Y TTM-47.29% Oper. Margin0.00% RSI (14)48.08 Volatility5.82% 7.79%
Employees126 Debt/Eq0.18 Sales Y/Y TTM- Profit Margin- Recom1.50 Target Price7.17
Option/ShortYes / Yes LT Debt/Eq0.16 EPS Q/Q81.42% Payout- Rel Volume4.21 Prev Close2.06
Sales Surprise- EPS Surprise11.74% Sales Q/Q- EarningsMar 27 AMC Avg Volume781.28K Price2.07
SMA20-5.34% SMA503.97% SMA200-8.80% Trades Volume836,989 Change0.24%
Date Action Analyst Rating Change Price Target Change
Mar-11-24Initiated CapitalOne Overweight $8
Jan-05-24Downgrade BofA Securities Buy → Neutral $11 → $6
Oct-11-23Initiated H.C. Wainwright Buy $10
Mar-30-23Initiated Mizuho Buy $9
Feb-24-23Initiated Goldman Buy $10
Feb-03-23Upgrade Morgan Stanley Equal-Weight → Overweight $15
Mar-27-24 10:53PM
08:30PM
04:01PM
Feb-14-24 08:00AM
Feb-01-24 08:00AM
08:00AM Loading…
Jan-03-24 08:00AM
Dec-20-23 01:34PM
Dec-11-23 08:00AM
Nov-28-23 08:00AM
Nov-09-23 04:01PM
Nov-08-23 08:00AM
Oct-12-23 11:28AM
Oct-10-23 03:56PM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
08:00AM Loading…
Aug-29-23 08:00AM
Aug-10-23 04:01PM
Jul-12-23 06:35AM
Jun-22-23 04:01PM
Jun-15-23 06:22AM
Jun-06-23 10:53AM
Jun-05-23 04:01PM
Jun-01-23 08:00AM
May-31-23 08:00AM
May-25-23 05:00PM
09:01AM
May-16-23 08:00AM
May-15-23 04:01PM
May-02-23 08:00AM
May-01-23 08:00AM
05:00PM Loading…
Apr-26-23 05:00PM
Apr-25-23 08:00AM
Apr-18-23 09:00AM
Apr-12-23 07:07AM
Apr-10-23 08:00AM
Mar-31-23 06:19AM
Mar-30-23 04:21AM
Mar-23-23 04:01PM
Mar-14-23 04:31PM
Feb-01-23 08:00AM
Jan-16-23 06:19AM
Jan-11-23 03:04PM
Jan-04-23 08:00AM
Dec-20-22 08:00AM
Dec-17-22 07:28AM
Dec-16-22 07:15AM
Dec-13-22 08:00AM
Dec-09-22 10:00AM
07:34AM
07:32AM
Nov-30-22 08:00AM
Nov-22-22 08:00AM
Nov-14-22 09:55AM
Nov-09-22 04:01PM
Oct-20-22 08:00AM
Oct-12-22 08:00AM
Sep-26-22 08:00AM
Sep-09-22 08:31AM
Sep-08-22 11:08AM
Sep-07-22 04:05PM
Aug-24-22 08:00AM
Aug-23-22 09:55AM
08:00AM
Aug-19-22 09:55AM
Aug-11-22 04:05PM
Aug-08-22 09:29AM
Aug-03-22 09:55AM
Jul-27-22 06:00PM
Jul-21-22 06:00PM
Jul-18-22 06:15PM
09:55AM
08:00AM
Jul-12-22 06:00PM
Jul-06-22 06:15PM
Jun-09-22 09:55AM
Jun-03-22 09:00AM
Jun-02-22 08:00AM
May-25-22 08:00AM
May-23-22 09:55AM
May-12-22 04:01PM
May-03-22 08:00AM
Apr-27-22 08:00AM
Apr-15-22 07:42AM
Apr-12-22 04:01PM
Apr-06-22 08:00AM
Mar-24-22 04:05PM
Mar-10-22 08:00AM
Mar-08-22 04:31PM
Mar-01-22 04:14PM
Feb-08-22 09:04AM
Feb-03-22 08:00AM
Jan-27-22 01:38PM
Jan-18-22 08:00AM
Jan-04-22 08:00AM
Dec-24-21 12:38AM
Dec-18-21 12:38AM
Dec-17-21 08:00AM
Dec-16-21 09:38AM
Dec-15-21 05:46AM
Dec-14-21 08:00AM
Erasca, Inc. is a clinical stage precision oncology company, It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 2, 2018 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lim Jonathan EChairman & CEODec 06 '23Buy1.72278,150478,41812,899,360Dec 06 07:41 PM
Start Valerie Denise HardingDirectorDec 06 '23Buy1.8510,00018,48020,000Dec 08 09:10 AM
Lim Jonathan EChairman & CEODec 05 '23Buy1.69721,8501,217,76112,899,360Dec 06 07:41 PM
Casdin Alexander W.DirectorDec 04 '23Buy1.6630,00049,785493,974Dec 04 06:23 PM
Lim Jonathan EChairman & CEOOct 05 '23Buy2.031,000,0002,026,00019,456,216Oct 10 08:00 AM
Lim Jonathan EChairman & CEOJun 08 '23Buy2.75100,000275,00018,396,216Jun 08 08:54 PM
Casdin Alexander W.DirectorApr 10 '23Buy2.7620,00055,230463,974Apr 11 08:23 AM